Stock Detail
ALKERMES INC
Sector: Biotechnology
Latest Quote @ Sat May 5 10:41:13 (15 min delayed)
| N/A |
N/A |
$31.69 |
+1.36 |
4.48% |
1.39M |
Last Day's Data
| $31.69 |
$31.78 |
$1.36 |
4.48% |
0.00 |
$30.33 |
| $30.31 |
$29.86 |
1.00 |
4.22B |
1.39M |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 33.03 |
32.36 |
31.11 |
30.44 |
29.19 |
Stock Profile
Alkermes, Inc. develops pharmaceutical products based on drug delivery technologies. The company's commercial product, Risperdal Consta, is an antipsychotic medication approved for use in schizophrenia and is marketed worldwide. Its product candidate under development, Vivitrex, is a once-a-month injection for the treatment of alcohol and opioid dependence. The company has a pipeline of extended-release injectable and pulmonary drug products based on its proprietary technologies, ProLease and Medisorb, as well as inhaled drug products based on AIR technology. The company has collaborations with Cephalon, Inc., Janssen-Cilag, Eli Lilly and Company, Serono S.A., and Amylin Pharmaceutical, Inc. Alkermes was founded in 1987 and is headquartered in Cambridge, Massachusetts.
